Our study aimed to evaluate the safety profile of anti-TNF drugs in pregnant women with psoriasis, with a focus on certolizumab, which is considered safer than adalimumab, etanercept, infliximab, and golimumab [33]. The gene discussed is TNF; the disease is psoriasis.